PRELI domain containing 3B pseudogene 3 (PRELID3BP3)

PRELI domain containing 3B pseudogene 3 (PRELID3BP3) is classified as a pseudogene, specifically annotated in humans as a processed pseudogene without known protein-coding capacity[1][3]. Its only known alias is SLMO2P3[1][3]. Pseudogenes like PRELID3BP3 are typically homologous to protein-coding genes but have accumulated sequence changes (such as frameshifts or stop codons) that prevent normal protein expression[4]. While some pseudogenes have demonstrated regulatory roles, acting via their RNA as competitive endogenous RNAs or sources of noncoding transcripts, there are no functional, disease, or pharmacological associations currently reported for PRELID3BP3 specifically[1][3]. No evidence supports its role as a receptor, enzyme, transporter, or any canonical drug target, nor is there evidence it acts as a biomarker or interacts with drugs[1][3][4]. It is not considered a therapeutic target; its classification as a pseudogene suggests a lack of normal biological or pharmacologic function and therapeutic relevance at this time. If your query is for drug discovery or therapeutic targeting, note that PRELID3BP3 is not an actionable target according to current knowledge.

Other names

SLMO2P3